Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Michael Morrissey | President and CEO, Director | $100M | Jan 16, 2025 | ||
David Edward Johnson | Director | $32M | +$12.7M | +65.4% | May 31, 2024 |
Christopher J. Senner | EVP and CFO | $30M | -$3.4M | -10.2% | Jan 16, 2025 |
Stelios Papadopoulos | Director | $26.6M | -$240K | -0.9% | May 31, 2024 |
Dana Aftab | CSO/EVP Disc & Trans Research | $21.4M | -$6.37M | -23% | Jan 16, 2025 |
Jeffrey Hessekiel | EVP & General Counsel | $21M | -$7.87M | -27.2% | Jan 16, 2025 |
Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | $16.1M | Jul 26, 2021 | ||
Patrick J. Haley | EVP, Commercial | $15.2M | -$3.15M | -17.1% | Jan 16, 2025 |
Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | $10.3M | Nov 15, 2024 | ||
Peter Lamb | EVP, Scientific Strategy & CSO | $9.79M | Dec 15, 2022 | ||
Lance Willsey | Director | $9.7M | May 26, 2022 | ||
Jack L. Wyszomierski | Director | $7.69M | -$416K | -5.13% | Jun 4, 2024 |
Vicki L. Goodman | EVP, Prod Dev & Med Aff &CMO | $7.03M | Apr 3, 2023 | ||
Charles Cohen | Director | $5.98M | Dec 31, 2021 | ||
George Poste | Director | $5.75M | -$2.17M | -27.4% | Nov 1, 2024 |
Maria C. Freire | Director | $2.42M | -$219K | -8.31% | Aug 14, 2024 |
Vincent T. Marchesi | Director | $2.15M | May 26, 2022 | ||
Jacqueline Wright | Director | $1.18M | Jun 1, 2023 | ||
Alan M. Garber | Director | $857K | -$461K | -35% | Mar 21, 2024 |
Tomas J. Heyman | Director | $768K | May 31, 2024 | ||
Bob Oliver | Director | $768K | May 31, 2024 | ||
Sue Gail Eckhardt | Director | $711K | May 31, 2024 | ||
Mary C. Beckerle | Director | $711K | May 31, 2024 | ||
Carl B. Feldbaum | Director | $428K | Feb 9, 2023 | ||
Julie Smith | Director | $292K | -$576K | -66.4% | Aug 13, 2024 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|